Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide inhalation suspension vs Pulmicort Respules in acute asthma exacerbation
CTR20200553Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide in asthma (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Change in FEV1 from baseline at 1 week. Started Apr 2020; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20200553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200553.